IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report report published on Wednesday morning. The firm issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Up 4.0 %

IRIX stock opened at $1.03 on Wednesday. IRIDEX has a 12 month low of $0.78 and a 12 month high of $3.65. The firm’s 50-day moving average is $1.33 and its 200 day moving average is $1.56. The company has a market capitalization of $17.29 million, a PE ratio of -1.54 and a beta of 0.94. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85.

IRIDEX (NASDAQ:IRIX) last issued its earnings results on Thursday, March 27th. The medical equipment provider reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $12.70 million for the quarter, compared to analyst estimates of $12.80 million. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.